DYME
Drug2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
NCT Number: NCT00596583
The primary objective of this study is to test the hypothesis that DYME is safe and effective as a drug to facilitate continuous curvilinear capsulorhexis (CCC) by selectively staining the anterior capsule. Secondary objectives are to compare the safety and effectiveness of DYME to that of a smaller dose of the same API.
Looking for future studies?
Notify Me18 year and older
All sexes
Interventional
Phase 3
Bhagwan Mahaveer Jain Hospital, Bangalore, Karnataka, India
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution
Time frame: During surgery
Time frame: one week post-op
Time frame: during surgery
Time frame: 1-day and 1-week post-op
Aqumen Biopharmaceuticals, N.A.
Industry
AQNA-DY001: A Double-Masked, Randomized Study of the Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.